Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell): Immediate Impact

Sponsor
Marc Pelletier (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05545930
Collaborator
ProCell Surgical Inc. (Other)
12
1
2
3.4
3.5

Study Details

Study Description

Brief Summary

The purpose of this research study is to compare two methods of recovering blood from surgical sponges used during heart and lung surgeries. The two methods are: 1) manually wringing sponges by hand, and 2) automated wringing sponges by an FDA approved suction device. Both methods are already in use in heart and lung surgeries at University Hospitals at the discretion of the surgeon.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Hand Wrung
  • Device: ProCell Wrung
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
12 participants
Allocation:
Non-Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Masking Description:
Subjects will be blinded to the order of intervention.
Primary Purpose:
Supportive Care
Official Title:
Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell): Immediate Impact
Anticipated Study Start Date :
Sep 19, 2022
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Hand Wrung

Hand wrung refers to manually wringing surgical sponges by hand.

Procedure: Hand Wrung
Hand wrung refers to manually wringing surgical sponges by hand.

Experimental: ProCell Wrung

ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).

Device: ProCell Wrung
ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).

Outcome Measures

Primary Outcome Measures

  1. Level of Plasma Free Hemoglobin [Baseline]

    Level of plasma free hemoglobin will be measured at baseline.

  2. Level of Plasma Free Hemoglobin [Post-Processing (Up to 120 Minutes)]

    Level of plasma free hemoglobin will be measured post-processing.

  3. Change in Volume of Blood [Baseline, Post-Processing (Up to 120 Minutes)]

    Volume of blood will be measured at baseline and post-processing.

Secondary Outcome Measures

  1. Number of Fragmented Red Blood Cells [Baseline]

    Number of fragmented red blood cells will be measured at baseline.

  2. Number of Fragmented Red Blood Cells [Post-Processing (Up to 120 Minutes)]

    Number of fragmented red blood cells will be measured post-processing.

  3. Level of Lactate Dehydrogenase [Baseline]

    Level of lactate dehydrogenase will be measured at baseline.

  4. Level of Lactate Dehydrogenase [Post-Processing (Up to 120 Minutes)]

    Level of lactate dehydrogenase will be measured post-processing.

  5. Level of Haptoglobin [Baseline]

    Level of haptoglobin will be measured at baseline.

  6. Level of Haptoglobin [Post-Processing (Up to 120 Minutes)]

    Level of haptoglobin will be measured post-processing.

  7. Change in Weight of Surgical Sponge [Baseline, Post-Procedure (Up to 5 Minutes)]

    Weight of surgical sponges will be measured at baseline and post-procedure.

  8. Time to Wring Sponges [Up to 120 Minutes]

    Time to wring sponges will be measured.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 89 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Undergoing heart or lung transplant, redo sternotomy, aortic surgery, and/or multi-valve repairs/replacements; and

  • At University Hospitals Cleveland Medical Center.

Exclusion Criteria:
  • Patients with known bleeding disorders, including disseminated intravascular coagulation (DIC), prothrombin deficiency, factor V deficiency, factor VII deficiency, factor X deficiency, factor XI deficiency (hemophilia C), Glanzmann disease, hemophilia A, hemophilia B, idiopathic thrombocytopenic purpura (ITP), and Von Willebrand disease (types I, II, and III);

  • Patients undergoing emergent or emergent salvage surgery; and

  • Patients actively participating in another clinical trial which could affect outcomes.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospitals Cleveland Medical Center Cleveland Ohio United States 44106

Sponsors and Collaborators

  • Marc Pelletier
  • ProCell Surgical Inc.

Investigators

  • Principal Investigator: Marc Pelletier, MD, University Hospitals Cleveland Medical Center
  • Principal Investigator: Craig Jarrett, MD, MBA, University Hospitals Cleveland Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Marc Pelletier, Division Chief, Cardiac Surgery, UH Cleveland Medical Center, University Hospitals Cleveland Medical Center
ClinicalTrials.gov Identifier:
NCT05545930
Other Study ID Numbers:
  • STUDY20220888_1
First Posted:
Sep 19, 2022
Last Update Posted:
Sep 19, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Marc Pelletier, Division Chief, Cardiac Surgery, UH Cleveland Medical Center, University Hospitals Cleveland Medical Center

Study Results

No Results Posted as of Sep 19, 2022